Piper Sandler Raises Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $11.00

Amneal Pharmaceuticals (NASDAQ:AMRX - Free Report) had its target price boosted by Piper Sandler from $9.00 to $11.00 in a report published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on AMRX. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target on the stock in a research report on Friday, September 6th. Finally, Barclays upped their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an "overweight" rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Amneal Pharmaceuticals Stock Up 5.4 %

AMRX traded up $0.47 during trading on Monday, reaching $9.20. The company's stock had a trading volume of 2,220,327 shares, compared to its average volume of 1,409,931. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -12.94 and a beta of 1.17. The firm has a fifty day simple moving average of $8.53 and a two-hundred day simple moving average of $7.56. Amneal Pharmaceuticals has a 1 year low of $4.15 and a 1 year high of $9.32.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The business had revenue of $701.78 million during the quarter, compared to the consensus estimate of $657.43 million. As a group, equities analysts forecast that Amneal Pharmaceuticals will post 0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Rothschild Investment LLC purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter worth $26,000. Gladius Capital Management LP acquired a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at about $37,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at about $42,000. nVerses Capital LLC acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth about $62,000. Finally, Atlanta Consulting Group Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals during the first quarter worth approximately $61,000. 31.82% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.